Abbisko Therapeutics Co, Ltd
Clinical trials sponsored by Abbisko Therapeutics Co, Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill for tough tumors enters human testing Results expected Dec 2026 (estimated)
- New hope for liver cancer: targeted drug ABSK-011 enters phase 2 trial Results expected Jun 2027 (estimated)
-
New drug combo aims to outsmart resistant lung cancer
Disease control Not yet recruitingThis phase 2 trial tests whether adding an experimental drug called ABSK043 to the standard targeted therapy osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutated, PD-L1 positive). The study enrolls adults whose cancer has spread or cannot be surg…
Phase 2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New daily pill aims to boost growth in kids with dwarfism
Disease control Not yet recruitingThis study tests a new drug called ABSK061 in children aged 3 to 12 with achondroplasia, a common form of dwarfism. The drug is taken once daily and aims to improve growth rate. The trial will first find a safe dose, then check how well it works over a year. About 110 children wi…
Phase 1/2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC